首頁 > 市場調查報告書 > 醫療設備

透析設備

市場調查報告書

商品編碼

1439540

Apheresis - 全球市場考量、競爭格局、市場預測 (2030)

Apheresis - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 2024年02月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

預計2022年全球單採市場規模將達到22.3066億美元，到2030年將達到36.7155億美元，在預測期內（2022-2028年）複合年增長率為8.75%。確實如此。預計該市場將受到鐮狀細胞性貧血、血癌等血液疾病日益流行、各種生物製藥公司對原料血漿的需求不斷增加以及預測期內（2024-2030年）單採系統推出的推動。由於批准增加等因素，市場預計將繁榮。

單採市場動態

在單採市場的顯著驅動因素中，血液疾病盛行率的增加是加速單採市場發展的主要因素。

例如，根據世界衛生組織 (WHO) (2023) 發布的數據，貧血是一個嚴重的全球公共衛生問題，影響幼兒和孕婦。世界衛生組織的估計與最近的研究一致，該研究表明全世界約 42% 的 5 歲以下兒童和 40% 的孕婦被認為患有貧血。

此外，根據美國國家癌症研究所（NCI）（2022）的數據，預計2022年美國將新增約60,650名白血病患者。

根據 Global Blood Therapeutics（2020 年）的報告，2019 年歐洲有超過 52,000 人受到鐮狀細胞疾病的影響。據同一消息來源稱，與人口相比，該疾病使預期壽命減少約 25 至 30 年，並且往往主要影響非洲、地中海和南亞人後裔。

展望未來，預計血液疾病盛行率的增加將增加對單採設備的需求，並在 2022-2028 年研究期間推動單採設備的整體市場成長。

與單採市場相關的另一個主要驅動因素是用於管理和治療各種疾病的創新單採設備的開發。

例如，2022 年 5 月，Baxter International Inc. 宣佈在全球推出其下一代平台的最新版本 PrisMax 2。 PrisMax 2 專為治療性血漿置換和其他器官支持護理而設計，為醫院提供靈活性，以滿足重症監護病房 (ICU) 的獨特需求。

此外，2020 年4 月，Terumo BCT, Inc. 和Marker Therapeutics AG 將Terumo BCT 的Spectra Optia(TM) 單採血液成分系統與Marker Therapeutics 的D2000 吸附盒結合，治療確診患有COVID-19的18 歲患者。美國 FDA 宣布已授予治療這些患者的緊急使用授權 (EUA)。

然而，與單採治療相關的高成本和各種風險可能會限制單採市場的成長。

單採血液成分市場在 COVID-19 大流行期間呈現正面成長。隨著COVID-19患者數量的不斷增加，血小板計數、纖維蛋白原、D-二聚體、凝血□原時間（PT）、活化部分凝血活□時間（APTT）等多種凝血參數已被發現為嚴重感染患者的併發症，因此血漿療法已被賦予廣泛的用途。恢復期血漿療法正在用於感染 COVID-19 的患者。此外，根據《柳葉刀》雜誌發表的一篇文章，2020年5月28日至2022年6月15日期間，16,287名登記在冊的恢復期患者中，有11,558名（71%）有資格接受恢復期血漿。 CP 療法包括從剛從感染中恢復的患者身上收集血漿並將其註射到有危險的人體內。因此，所有這些因素都對疫情期間全球單採市場的成長產生了積極影響。

隨著大量人群接種疫苗以及包括醫療保健行業在內的各行業活動的恢復，單採血液成分市場預計在 2024-2030 年預測期內將進一步實現正增長。

本報告研究和分析了全球單採市場，提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。

推動單採血液成分市場的因素
- 血液疾病盛行率不斷上升
- 生藥廠對原料血漿的需求不斷增加
- 與單採手術相關的優惠報銷政策和資金
單採市場的抑制因素與挑戰
- 與單採治療相關的高成本
- 與血漿分離術治療相關的風險
單採術市場機遇
- 專為兒童設計的新型單採療法的創新和研發激增
- 降低脂蛋白分離術的成本，廣泛提供治療

第5章波特五力分析單採市場

第6章COVID-19對單採市場的影響分析

第7章單採市場佈局

依產品類型
- 單採機
- 一次性物品
按技術
- 離心
- 薄膜過濾
透過治療
- 白血球去除手術
- 血漿置換
- 血小板交換
- 紅血球去除療法
- 其他
依用途
- 腎臟疾病
- 血液疾病
- 神經系統疾病
- 自體免疫疾病
按地區
- 北美
- 歐洲
- 亞太地區
- 其他領域

第 8 章血漿分離術市場：全球公司份額分析 - 3 至 5 家主要公司

第9章單採市場公司與產品概況

Braun Melsungen AG
Asahi Kasei Corporation
Fresenius Kabi AG
Haemonetics Corporation
Terumo Corporation
Baxter International
Kaneka Corporation
Sumitomo Bakelite Company Limited
Medica SPA
Nikkiso Co., Ltd.
Cerus Corporation
Miltenyi Biotec B.V.& Co. KG
Haier Inc.
Otsuka Holdings

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

簡介目錄圖表

Product Code: DIMDCL0364

Apheresis Market By Product Type (Apheresis Machine And Disposable), By Technology (Centrifugation And Membrane Filtration), By Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis And Others), By Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Automune Disorders, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2024-2030 owing to the rising increasing prevalence of hematological disorders and rise in the requirement of source plasma by various biopharmaceutical companies

The global apheresis market was valued at USD 2,230.66 million in 2022 and is estimated to grow at a CAGR of 8.75% during the forecast period (2022-2028) to reach USD 3,671.55 million by 2030. The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2024-2030).

Apheresis Market Dynamics:

Among the noteworthy drivers of the apheresis market, the rising prevalence of hematological disorders turns out to be the major factor for accelerating the apheresis market.

For example, as per the data published by the World Health Organization (2023), anemia is a serious global public health problem that affects both young children and pregnant women. WHO estimates are in accordance with recent studies, and observes that about 42% of children less than 5 years of age and about 40% of the pregnant women are anemic globally.

Moreover, as per the National Cancer Institute 2022 (NCI), it has been estimated that there will be around 60,650 new cases of leukemia in the United States in 2022.

The report by Global Blood Therapeutics 2020 showed that sickle cell disease affected more than 52,000 people living in Europe in 2019. As per the same source, the condition carries a life expectancy of about 25 to 30 years below the general population and tends to predominantly affect the African, Mediterranean and the South Asian descent people.

Henceforth, the increasing prevalence of hematological disorders, will increase the demand for apheresis devices, which is anticipated to propel the overall market growth of the apheresis devices in the study period of 2022 - 2028.

Another major driver pertaining to the apheresis market is the development of innovative apheresis devices for the management and treatment of various diseases.

For example, in May 2022, Baxter International Inc., announced the global launch of PrisMax 2, the latest version of the company's next-generation platform. PrisMax 2 is designed for therapeutic plasma exchange therapy and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU).

Furthermore, in April 2020, Terumo BCT, Inc. and Marker Therapeutics AG announced that the US FDA has issued Emergency Use Authorization for the use of Terumo BCT's Spectra Optia(TM) Apheresis System combined with Marker Therapeutics' D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed COVID-19.

However, high costs and the various risks associated with apheresis treatment may act as restraining factors for the apheresis market growth.

The apheresis market reported a period of positive growth during the COVID-19 pandemic. Owing to rise in the COVID-19 cases, various coagulation parameters such as the platelet count, fibrinogen, D-dimmer, prothrombin time (PT), activated partial thromboplastin time (aPTT), were found as a complication among the patients that were severely infected, thus extensive applications pertaining to plasma therapies were given. The convalescent plasma therapy is used in patients that got infected due to COVID-19. Moreover, as per the article published in the Lancet Journal, between May 28, 2020 and June 15, 2022, 11558 (71%) of 16287 patients enrolled in recovery were eligible to receive convalescent plasma. CP therapy involves the collection of plasma from the patient's body who has recently recovered from infection and infusion of that collected plasma into the body of the individuals that are at a risk. Thus, all these factors had positively impacted the growth of the global apheresis market during the pandemic.

With large number of masses being vaccinated and with the resumption of activities across industries including the healthcare sector, the apheresis market is further expected to grow positively during the forecast period from 2024-2030.

Apheresis Market Segment Analysis:

Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the apheresis market, the disposables category is projected to register a significant growth in revenue and was valued at USD 1,376.18 million in 2022 and will grow at a CAGR of 8.26% during the forecast period (2022-2028) to reach USD 2,204.25 million by 2030.

This can be can be attributed to the increased consumption of disposables in the process of apheresis. The disposables present in apheresis machines are manufactured and designed exclusively for one-time use, in order to ensure contamination-free transfer of blood components and maintain sterile conditions. Disposables form a key component for any apheresis system to deliver quality treatment, because of which all the key market players ensure a strong disposable kit profile for their apheresis systems. The Plasmat Futura Kit from B. Braun Melsungen AG, LIFE 21? and LIFE 18(TM) apheresis units disposables from Miltenyi Biotec, disposable TPE 2000 Set for PRISMAFLEX System from Baxter are some of the examples of quality disposables manufactured by key companies in order to build and flourish their market for apheresis.

In addition, recent developments by big market players in order to expand their expertise to more advanced disposable systems is further expected to boost the demand for disposables. For example, in January 2020, Fresenius Kabi AG inaugurated the expansion of the company's production site in Dominican Republic, having advanced production equipment, plasma kit assembly lines and sterilization units, enabling the company to meet the rising demand for high-quality disposables.

Hence, the interplay of all the aforementioned factors is anticipated to propel the market for disposables in the upcoming years.

North America is expected to dominate the overall Apheresis Market:

Among all the regions, North America is expected to lead in revenue generation in the global apheresis market and was valued at USD 979.12 million in 2022. It will grow at a CAGR of 8.44% during the forecast period from 2024 to 2030 to reach USD 1,584.64 million by 2030.

This domination is due to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of apheresis market in the North America region.

According to the figures provided by American Cancer Society 2022, it is estimated that there will be nearly 60,650 news cases of leukemia in the year 2023 in the United States. As per the National Cancer Institute 2022, in the year 2019, there were an estimated 472,714 people living with leukemia in the United States. The above statics clearly indicates that the incidence of leukemia is surging every year.

White blood cell reduction apheresis is primarily used as a treatment for patients with leukemia whose blood white cell counts are excessively high. Thus, the increasing prevalence of leukemia in the United Sates will increase the demand of apheresis in the market.

The American Association for the Surgery of Trauma reports that in the United States, injury accounts for over 150,000 deaths and over 3 million non-fatal injuries per year. The injuries undergo some sort of surgical procedure for its treatment or management. Surgical procedure are usually accompanied with blood or blood components transfusion and the blood components can be separated and stored with the aid of apheresis. Therefore, the increasing number of injuries will shoot up the number of surgical procedures, thereby increasing the demand of blood component transfusion, henceforth propelling the demand for apheresis in the market.

Therefore, along with the presence of large number of geriatric patients prone to chronic disorders in North America and the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the apheresis market in the overall North America region during the forecast period.

Apheresis Market Key Players:

Some of the key market players operating in the apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.

Recent Developmental Activities in Apheresis Market:

In June 2022, Terumo, a medical technology company, announces that the UK's NHS England has selected the Spectra OptiaR Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.

In May 2022, Terumo, a medical technology company, announces that the UK's NHS England has selected the Spectra OptiaR Apheresis System through the NHS MedTech Funding Mandate to treat sickle cell disease. As a result, Spectra Optia will be deployed more widely in hospitals across England.

In January 2020, Fresenius Kabi unveiled Euro 30 million expansion of transfusion and apheresis disposables plant in Dominican Republic. The top government and company officials joined local executives and employees for the company's production site in the Dominican Republic.

Key Takeaways from the Apheresis Market Report Study

Market size analysis for current apheresis market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the apheresis market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
Key companies dominating the global apheresis market.
Various opportunities available for the other competitor in the apheresis market space.
What are the top performing segments in 2023? How these segments will perform in 2030.
Which is the top-performing regions and countries in the current apheresis market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for apheresis market growth in the coming future?

Target Audience who can be benefited from this Apheresis Market Report Study

Apheresis products providers
Research organizations and consulting companies
Apheresis-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in apheresis machines and disposables
Various end users who want to know more about the apheresis market and latest technological developments in the apheresis market.

Frequently Asked Questions for Apheresis Market:

1. What is apheresis?

Apheresis is a medical technology used to separate various constituents of the blood, in which the remaining components of the blood are returned to the patient after extraction of the desired component (viz. erythrocytes, leukocytes, plasma, platelets etc.).

2. What is the market for the global Apheresis?

The global apheresis market was valued at USD 2,230.66 million in 2022 and is estimated to grow at a CAGR of 8.75% during the forecast period (2022-2028) to reach USD 3,671.55 million by 2030.

3. What are the drivers for the global Apheresis market?

The apheresis market is slated to witness prosperity owing to factors such as the increasing prevalence of hematological disorders such as sickle cell, anemia, blood cancers among others, the rise in the requirement of source plasma by various biopharmaceutical companies and an increase in the launch and approval of apheresis systems during the forecast period (2024-2030).

4. Who are the key players operating in the global Apheresis market?

Some of the key market players operating in the Apheresis market include Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter International, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V & Co., KG, Haier Inc., Otsuka Holdings and others.

5. Which region has the highest share in the Apheresis market?

North America is expected to dominate the overall apheresis market during the forecast period, 2024 to 2030. This can be ascribed to the rising prevalence of chronic diseases and cancers in the region. Moreover, the increase in the number of complex surgical procedures and the rising demand for blood components will also aid in the growth of the apheresis market in the North America region.

1.Apheresis Market Report Introduction

2.Apheresis Market Executive Summary

2.1. Scope of the Study
2.2. Market at Glance
2.3. Competitive Assessment

3. Regulatory Analysis

3.1. The United States
3.2. Europe
3.3. Japan
3.4. China

4. Apheresis Market Key Factors Analysis

4.1. Apheresis Market Drivers
- 4.1.1. Increasing prevalence of hematological disorders
- 4.1.2. Rising demand of source plasma from biopharmaceutical companies.
- 4.1.3. Favorable reimbursement policies and funding associated with apheresis procedures
4.2. Apheresis Market Restraints and Challenges
- 4.2.1. High cost involved in apheresis treatment
- 4.2.2. Risks associated with the apheresis treatment
4.3. Apheresis Market Opportunities
- 4.3.1. Surge in innovation and R&D for new apheresis treatment methods, specially designed for children
- 4.3.2. Reduction in the cost of lipoprotein apheresis and widespread availability of the therapy.

5. Apheresis Market Porter's Five Forces Analysis

5.1. Bargaining Power of Suppliers
5.2. Bargaining Power of Consumers
5.3. Threat of New Entrants
5.4. Threat of Substitutes
5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Apheresis Market

7. Apheresis Market Layout

7.1. By Product Type
- 7.1.1. Apheresis machines
- 7.1.2. Disposables
7.2. By Technology
- 7.2.1. Centrifugation
- 7.2.2. Membrane filtration
7.3. By Procedure
- 7.3.1. Leukapheresis
- 7.3.2. Plasmapheresis
- 7.3.3. Plateletpheresis
- 7.3.4. Erythrocytapheresis
- 7.3.5. Others
7.4. By Application
- 7.4.1. Renal Disorders
- 7.4.2. Hematological Disorders
- 7.4.3. Neurological Disorders
- 7.4.4. Autoimmune Disorders
- 7.4.5. Others
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. United States Apheresis Market in USD million (2021-2030)
  - 7.5.1.2. Canada Apheresis Market in USD million (2021-2030)
  - 7.5.1.3. Mexico Apheresis Market in USD million (2021-2030)
- 7.5.2. Europe
  - 7.5.2.1. France Apheresis Market in USD million (2021-2030)
  - 7.5.2.2. Germany Apheresis Market in USD million (2021-2030)
  - 7.5.2.3. United Kingdom Apheresis Market in USD million (2021-2030)
  - 7.5.2.4. Italy Apheresis Market in USD million (2021-2030)
  - 7.5.2.5. Spain Apheresis Market in USD million (2021-2030)
  - 7.5.2.6. Rest of Europe Apheresis Market in USD million (2021-2030)
- 7.5.3. Asia-Pacific
  - 7.5.3.1. China Apheresis Market in USD million (2021-2030)
  - 7.5.3.2. Japan Apheresis Market in USD million (2021-2030)
  - 7.5.3.3. India Apheresis Market in USD million (2021-2030)
  - 7.5.3.4. Australia Apheresis Market in USD million (2021-2030)
  - 7.5.3.5. South Korea Apheresis Market in USD million (2021-2030)
  - 7.5.3.6. Rest of Asia Pacific Apheresis Market in USD million (2021-2030)
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. Middle East Apheresis Market in USD million (2021-2030)
  - 7.5.4.2. Africa Apheresis Market in USD million (2021-2030)
  - 7.5.4.3. South America Apheresis Market in USD million (2021-2030)

8. Apheresis Market Global Company Share Analysis - Key 3-5 Companies

9. Apheresis Market Company and Product Profiles

9.1. Braun Melsungen AG
- 9.1.1. Company Overview
- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4. Product Listing
- 9.1.5. Entropy
9.2. Asahi Kasei Corporation
- 9.2.1. Company Overview
- 9.2.2. Company Snapshot
- 9.2.3. Financial Overview
- 9.2.4. Product Listing
- 9.2.5. Entropy
9.3. Fresenius Kabi AG
- 9.3.1. Company Overview
- 9.3.2. Company Snapshot
- 9.3.3. Financial Overview
- 9.3.4. Product Listing
- 9.3.5. Entropy
9.4. Haemonetics Corporation
- 9.4.1. Company Overview
- 9.4.2. Company Snapshot
- 9.4.3. Financial Overview
- 9.4.4. Product Listing
- 9.4.5. Entropy
9.5. Terumo Corporation
- 9.5.1. Company Overview
- 9.5.2. Company Snapshot
- 9.5.3. Financial Overview
- 9.5.4. Product Listing
- 9.5.5. Entropy
9.6. Baxter International
- 9.6.1. Company Overview
- 9.6.2. Company Snapshot
- 9.6.3. Financial Overview
- 9.6.4. Product Listing
- 9.6.5. Entropy
9.7. Kaneka Corporation
- 9.7.1. Company Overview
- 9.7.2. Company Snapshot
- 9.7.3. Financial Overview
- 9.7.4. Product Listing
- 9.7.5. Entropy
9.8. Sumitomo Bakelite Company Limited
- 9.8.1. Company Overview
- 9.8.2. Company Snapshot
- 9.8.3. Financial Overview
- 9.8.4. Product Listing
- 9.8.5. Entropy
9.9. Medica SPA
- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4. Product Listing
- 9.9.5. Entropy
9.10. Nikkiso Co., Ltd.
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4. Product Listing
- 9.10.5. Entropy
9.11. Cerus Corporation
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4. Product Listing
- 9.11.5. Entropy
9.12. Miltenyi Biotec B.V. & Co. KG
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4. Product Listing
- 9.12.5. Entropy
9.13. Haier Inc.
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4. Product Listing
- 9.13.5. Entropy
9.14. Otsuka Holdings
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4. Product Listing
- 9.14.5. Entropy